Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC
This single-arm phase II study investigated whether patients with refractory metastatic colorectal cancer who previously responded to irinotecan could benefit from high-dose irinotecan rechallenge, with dosing adjusted based on